-

Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Blueprint insiders received substantial benefits as part of change of control arrangements and certain insiders may have had conflicts of interests.

We are investigating whether the transaction offering documents may have contained materially misleading information and/or omissions.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Industry:

Ademi & Fruchter LLP

NASDAQ:BPMC
Release Versions
English

Contacts

Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

More News From Ademi & Fruchter LLP

Shareholder Alert: The Ademi Firm Investigates Whether 89bio, Inc. is Obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating 89bio (Nasdaq: ETNB) for possible breaches of fiduciary duty and other violations of law in its transaction with Roche. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-tradeable CVR to receive certain milestone payme...

Shareholder Alert: The Ademi Firm Investigates Whether Paramount Group Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Paramount (NYSE: PGRE) for possible breaches of fiduciary duty and other violations of law in its transaction with a Rithm Capital. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of Paramount will receive $6.60 per fully diluted share in an all-cash transaction valued at approximately...

Shareholder Alert: The Ademi Firm Continues to Investigate Whether TEGNA Inc. is Obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating TEGNA (NYSE: TEGNA) for possible breaches of fiduciary duty and other violations of law in its going-private transaction. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of TEGNA will receive $22.00 per share in an all-cash transaction valued at $6.2 billion, including TEGNA's net debt...
Back to Newsroom